IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes

IQVIA says sponsors can use the models to simulate studies and test assumptions before clinical trial execution.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Life Science Models^TM to help predict clinical trial outcomes.

IQVIA Life Science Models are a suite of purpose-built models for life sciences, combining IQVIA’s proprietary expert content, deep domain knowledge and established regulatory, compliance and privacy frameworks. Built using technologies including NVIDIA Nemotron^TM and supported by Amazon Web Services (AWS) infrastructure, the models connect molecular and treatment information with patient journeys and clinical outcomes to enable predictive applications across clinical development.

• Clinical study simulation and protocol optimization, including endpoint selection, patient eligibility criteria, dose selection and sample size planning, helping teams identify risks before trials begin. In initial evaluation across 50 trials and 270 endpoints, 85% of predictions were on target or clinically close.
• Digital twins and synthetic controls that support more efficient study designs.
• Leverage clinical study predictions to inform better real-world planning and access.

In clinical development, Life Science Models extend IQVIA’s Predictive Clinical Development approach, enabling sponsors to simulate studies and test key assumptions before execution, helping optimize study design and identify potential risks earlier.

To learn more, visit IQVIA Life Science Models.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI^®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

IQVIAFIN

View source version on businesswire.com: https://www.businesswire.com/news/home/20261007011389/en/

Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558

Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com)
+1.919.923.6785

Source: IQVIA

Key Terms

endpoints medical

Endpoints are specific points or limits used to mark the beginning or end of a process, measurement, or assessment. For investors, they help define clear boundaries for evaluating performance or outcomes, much like setting start and finish lines in a race. Knowing the endpoints allows investors to understand results accurately and make informed decisions based on those defined boundaries.

digital twins technical

Digital twins are virtual replicas of physical objects, systems, or processes that simulate their real-world counterparts in real time. They allow users to monitor, analyze, and predict how the actual entity will behave under different conditions. For investors, digital twins can provide valuable insights into performance and potential risks, helping to make better-informed decisions.

synthetic controls medical

A synthetic control is a statistical method for estimating what would have happened to a single unit (a company, region, or market) if a specific event or intervention had not occurred. It constructs a “synthetic” version of that unit by taking a weighted combination of similar units that were not exposed to the event, and then compares the actual outcome to the synthetic one to measure the event’s effect; accuracy depends on finding donor units whose pre-event behavior closely matches the treated unit.